We assessed the association between preoperative use of metformin and statin, alone or in combination, with biochemical recurrence (BCR) after radical prostatectomy (RP) in 843 men with diabetes. We also tested whether these associations varied as a function of race and/or body mass index (BMI). Preoperative statin use was associated with worse BCR risk, especially among men with a high BMI, but these associations may be mitigated by concomitant use of metformin. Purpose: To investigate the preoperative use of combination metformin and statin versus monotherapy on biochemical recurrence (BCR) after radical prostatectomy (RP) in diabetic men. Patients and Methods: Data of 843 diabetic men who underwent RP were stratified on the basis of preoperative use of no drug or of metformin, statin, or both. Multivariable Cox models were used to test the association between treatment and BCR. In a secondary analysis, models were stratified by race and body mass index (BMI) and further adjusted for glycated hemoglobin (HbA1c). Results: A total of 259 men (31%) received statin therapy, 94 (11%) metformin, 307 (36%) metformin þ statin, and 183 (22%) neither. Five-year BCR-free survival rates were 75% in metformin only versus 75% in metformin þ statin versus 60% in statin versus 68% in no drug groups (log-rank, P ¼ .003). On multivariable analysis, preoperative statin use was associated with increased BCR risk versus men receiving neither drug (hazard ratio [HR] ¼ 1.84; 95% confidence interval [CI], 1.28-2.64). Metformin alone (HR 0.88; 95% CI, 0.53-1.47) and metformin þ statin (HR 0.88; 95% CI, 0.58-1.33) were unrelated to BCR risks. In secondary analysis, the association between statin use and higher BCR risk was similar regardless of race, but was stronger among men with BMI ! 30 kg/m 2 (HR 3.12; 95% CI,). These results were largely unchanged after adjusting for HbA1c.
Introduction
At the population level, diabetes is associated with a decreased risk of prostate cancer. 1 However, some studies among men with prostate cancer have shown an association between diabetes and high-grade disease. 2, 3 Whether these associations are driven by diabetes itself, the associated metabolic syndrome in these patients, or the medications used to treat diabetes is unclear. Specifically, because of its good safety profile, metformin, which may have anticancer activities, is widely used in patients with diabetes. It facilitates glucose uptake in peripheral tissues and reduces hepatic conversion of glycogen to glucose. 4 In recent years, several in vivo and in vitro studies found that metformin reduced proliferation and increased apoptosis in prostate cancer cell lines. [5] [6] [7] [8] Whereas these data suggest metformin use in men with prostate cancer can lead to improved outcomes, other studies found no associations. [9] [10] [11] [12] In a preprostatectomy randomized trial, it has been shown that oral metformin intake leads to increased tissue levels in the prostate, providing biological plausibility to the hypothesis that metformin may have direct antieprostate cancer activity in humans. 6 Another commonly used drug class that has generated interest for its antieprostate cancer effects is statins. Indeed, a meta-analysis of 27 observational studies has shown that statin use can reduce the risk of total and clinically significant prostate cancer by 7% and 20%, respectively. 13 Given the low toxicity of both metformin and statin, there is growing interest in using both drugs together, and many clinical guidelines recommend their combination therapy in patients with diabetes.
14, 15 Wang et al 7 showed the synergistic effect of metformin and atorvastatin combination therapy on activation of apoptotic pathways and induction of cell-cycle arrest on human prostate cancer cells cultured in vitro and when implanted into immune-deficient mice. To date, however, only one study has examined the combined effect of metformin and statin on prostate cancer outcomes, finding that the combination leads to synergistic effects to lower the risk of biochemical recurrence (BCR) after radical prostatectomy (RP). 16 In the present study, we tested the association between preoperative use of metformin and statin, alone or in combination, with BCR after RP in patients with diabetes. We also tested whether these associations varied as a function of race and/or body mass index (BMI).
Patients and Methods
After obtaining institutional review board approval, data on men who were treated with RP between 2000 and 2016 at 6 Veterans Affairs medical centers (West Los Angeles, San Diego, and Palo Alto, CA; Asheville and Durham, NC; Augusta, GA) were extracted into the Shared Equal Access Regional Cancer Hospital (SEARCH) database (n ¼ 3802). The database excluded men who received any neoadjuvant treatment. Inclusion criteria were men diagnosed before RP with diabetes by International Classification of Disease (ICD)-9 or ICD-10 codes (n ¼ 895). Information on medications was captured from pharmacy records. Patients who filled any prescription for any statin or metformin in the year before were considered as receiving therapy with the medication at the time of surgery. Followup protocols varied according to the treating physician, but BCR was defined as a single serum prostate-specific antigen (PSA) level of > 0.2 ng/mL, 2 consecutive PSA levels at 0.2 ng/mL, or secondary treatment for a rising PSA. Patients missing follow-up (n ¼ 17) or data on covariates (n ¼ 35) were excluded, resulting in a final study cohort of 843 men (Supplemental Figure 1 in the online version).
Patient characteristics were compared among 4 groups (no medication [control] , metformin only, statin only, and statin and metformin) by the chi-square test for categorical variables and the Kruskal-Wallis test for continuous variables. A Kaplan-Meier curve was created to show the relationship among the treatment groups and time to BCR. Differences in time to BCR were calculated by a log-rank test.
Our primary outcome was to test the association between the treatment groups and hazard of BCR, which was done using Cox proportional hazards models. All assumptions of the Cox models were tested and were met for all covariates. Multivariable models were adjusted for demographic variables: age (continuous), race (black vs. nonblack), BMI (continuous, log-transformed), PSA level (continuous, log transformed), year of surgery (continuous), surgical center and tumor characteristics (pathologic Gleason group; categorical, 1-5), positive surgical margin (yes vs. no), seminal vesicle invasion (yes vs. no), extracapsular extension (yes vs. no), and positive lymph nodes (yes vs. no vs. not performed). Because data were missing for 136 men regarding preoperative glycated hemoglobin (HbA1c) level in the year before surgery, this was not included as a covariate in the primary analysis to increase power, though we did adjust for HbA1c level in a sensitivity analysis. To test whether adjuvant treatment influenced our results, we repeated the analysis excluding men who received adjuvant treatment.
Secondary analyses were performed to test whether associations differed by race (black vs. nonblack) or BMI (< 30 vs. ! 30 kg/m 2 ).
For this analysis, given the reduced power to detect interactions in general, groups with similar outcomes were grouped together, leading to treatment being grouped as no treatment, statin only, or metformin with or without statin. Interactions were tested among treatment, race, and BMI by including a cross-product term in the model. Finally, sensitivity analyses were performed adjusting for Charlson comorbidity index. 17 Analyses were performed by Stata 15.0 (StataCorp, College Station, TX). P < .05 was considered statistically significant.
Results
In the SEARCH database, 843 diabetic men receiving statins (n ¼ 259), metformin (n ¼ 94), metformin þ statin (n ¼ 307), or neither (n ¼ 183) in the year before RP were categorized into 4 groups ( Table 1) . About 80% of patients received a lipophilic statin (simvastatin, atorvastatin, or lovastatin), while the rest received a hydrophilic statin. Overall, patients receiving metformin þ statin were less likely to be black (P < .001), had a higher median BMI (P ¼ .002), had lower preoperative PSA levels (P ¼ .003), and received RP in a more recent year (P < .001). There were no associations between preoperative receipt of metformin, statin, or both and grade groups, seminal vesicle invasion, extracapsular extension, or lymph node involvement (P > .09). However, the rate of a positive margin was significantly lower in men receiving metformin either alone (34%) or in combination with statin (37%) compared to patients receiving statins only (46%) or no drugs (47%) (P ¼ .021) ( Table 1) .
The median (interquartile range) follow-up period was 60 (29-97) months and did not vary by preoperative drug treatment group (P ¼ .79). BCR was detected in 266 (32%) of 843 patients. Fiveyear BCR-free survival rates differed significantly across groups, with the lowest rate in the statin-only group (60%) compared to the control group (68%), and was similar in those receiving only metformin (75%) versus metformin and statin (75%) (log-rank test; P ¼ .003, Figure 1 ). On multivariable analysis, preoperative medication therapy remained associated with BCR after RP among diabetic patients (P < .001). Specifically, preoperative statin use was Table 2 in the online version). The full multivariable model, adjusted for all variables, is provided in Supplemental Table 3 in the online version.
In secondary analysis, we assessed whether the effects of preoperative use of statin or metformin with or without statin on BCR differed between black and nonblack (94% white) patients. When stratified by race, and after adjusting for demographic, clinical, and pathologic variables, preoperative medication use was significantly associated with BCR in both races with no interaction (P ¼ .60), with patients receiving statins having the highest recurrence risk (HR ¼ 1.75-1.85), and men receiving metformin with or without statins had similar risk as men receiving neither medication (Table 3 ). The same was true when we adjusted the groups for smoking status (Supplemental Table 1 in the online version) and Charlson comorbidity index (Supplemental Table 4 (Table 3) .
However, there was no significant interaction between BMI and treatment group (P ¼ .50).
Discussion
Metformin and statins both affect several key molecular mechanisms that are important for prostate cancer progression, which has generated interest in their anticancer activities. Recently, the possible synergistic effects of metformin and statin to slow prostate cancer growth have been shown in animal models, and suggested by 
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Clinical Genitourinary Cancer February 2019 -e143 a single human observational study among diabetic men. 7, 16 In the current retrospective study, we investigated the risk of BCR after RP in patients with diabetes who received metformin and/or statin. We found no significant associations between lower BCR risk with metformin, statin, or their combination. In fact, men receiving statins alone had a significantly increased risk of BCR. Interestingly, this increased risk was not observed in men receiving dual therapy (ie, metformin and statins). Our results do not support the hypothesis that the combination of metformin plus statins leads to synergistic antieprostate cancer activity. Metformin has 2 potential antineoplastic properties. The first is to lower systemic insulin levels as a key growth factor for many cancers, including prostate cancer. 18, 19 The second is through metformin's effect as an activator of AMP-activated protein kinase, which stimulates glycolysis and fatty acid oxidation to generate adenosine triphosphate and which at the same time inhibits gluconeogenesis and mammalian target of rapamycin pathways. Suppression in protein and fatty acid synthesis impairs cell division, growth, and proliferation, leading to cell-cycle arrest. 20, 21 Potential antineoplastic mechanisms of statins include induction of apoptosis (Ras inhibition, caspase activation) and interfering with cholesterol-dependent pathways and structures such as cell membrane, androgen-dependent signaling, and G 1 -S and G 2 -M cell-cycle transitions.
22-24
A prior meta-analysis showed no effect of statins on BCR after RP (HR ¼ 0.94, P ¼ .43). 25 However, the studies that comprised the meta-analysis did not limit analyses to subjects with diabetes. We previously showed in our SEARCH cohort that statin use before RP was associated with a 30% lower risk of BCR (HR ¼ 0.70, P ¼ .03), but in men with high BMI (> 35 kg/m 2 ), statins were associated with a significantly increased BCR risk (HR ¼ 15.7, P ¼ .001). As such, our data suggested that in men who are obese and therefore more likely to have insulin resistance or diabetes, statins may increase BCR risk. 26 Consistent with this, in the current study of men who all had diabetes, we found that statins alone were associated with a significantly increased risk of BCR, and that the association was stronger among men with higher BMI. Of note, we have seen similar suggestions of an interaction between statins and BMI in a prior study of men undergoing biopsy, where although statins were unrelated to prostate cancer risk, among those with BMI > 30 kg/m 2 , statins were suggestively associated with increased risk of low-grade prostate cancer versus no cancer. 27 Thus, across several different cohorts, there are some data to suggest that for men who are diabetic or who high BMI, statins may be associated with an increased risk of prostate cancer and prostate cancer progression. Further research is needed to better understand these associations, and if confirmed, to understand the mechanistic bases for these observations. In this study, we found no association between BCR and metformin use, whether adjusted for HbA1c levels or not. This null association has also been shown in other studies. 10, 11 A metaanalysis of 9 retrospective, cohort, and caseecontrol studies showed a suggestion of an association between metformin and reduced BCR risk (HR ¼ 0.82, P ¼ .06), though this association was not statistically significant. 12 Of note, the HR for metformin in our study was similar (HR ¼ 0.88), though likewise, this was not statistically significant. Importantly, these studies all examined associations and therefore cannot assess causality. However, should the association between metformin and lower BCR risk prove to be true and caused by metformin, it is unlikely that this modest degree of reducing BCR risk would be clinically useful. Interestingly, although we found statins were associated with increased BCR risk, the combination of statins and metformin was 
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e144 -Clinical Genitourinary Cancer February 2019 unrelated to BCR risk. As such, receipt of metformin appeared to negate the excess risk of BCR associated with statins. However, we found no evidence that receiving the combination of metformin and statins was associated with improved outcomes. This differs from a prior animal study 7 as well as a single RP study, 16 both of which showed that the combination was associated with improved prostate cancer outcomes. Of note, given our study was observational, we cannot make any claims regarding possible mechanisms. However, if future studies confirm that metformin negates the adverse BCR risk after RP from statins in diabetic men, one possible explanation is that statins can lead to insulin resistance, 28 which may be counteracted by metformin's insulin-lowering properties. Alternatively, many men with diabetes may have metabolic syndrome, which is associated with worse outcomes (https://diabetesed.net/ page/_files/Diabetes-Mellitus-and-Metabolic-Syndrome.PDF). As such, it may not be the statins themselves but rather the underlying metabolic syndrome that leads to worse outcomes. Ultimately, if confirmed, further studies are needed to understand the basis for these associations. Our study has several strengths, including our ability to adjust for key demographic, clinical, and pathologic features as well as HbA1c level (as a marker of overall serum glucose level control). However, several limitations of this study also deserve mention. Because we only studied diabetic men, our results only apply to men with diabetes and prostate cancer. Future studies are needed to understand the potential role of statins and metformin in nondiabetic men. Unfortunately, details regarding diabetes severity or duration were not readily available. While we did adjust for HbA1c level and the results were unchanged, whether adjusting for other markers of diabetes severity would alter our results in unknown. Likewise, we did not capture other medication use that may help explain our findings (ie, insulin use). We did not differentiate between type 1 (insulin dependent) and type 2 (noneinsulin dependent) diabetes. However, because type 2 diabetes constitutes 90% to 95% of adult cases, it is unlikely that the lack of differentiation would markedly alter our findings. As with all retrospective studies, patients were not randomized to the various treatments. As such, unmeasured residual confounding factors and baseline imbalances may have affected our results. Furthermore, we stratified patients on the basis of their preoperative medication use. However, it is possible that men began or stopped receiving these medications during follow-up but before BCR. Misclassification of patients to a particular group would bias the results to the null and would not explain a positive association such as we saw with statins and increased BCR risk. Our database did not include information as to when the men initiated their medications or the dose. Thus, we were not able to assess the association among duration of drug use, dose, and outcome.
Conclusion
In this retrospective study of diabetic men undergoing RP, preoperative use of statins was associated with a higher risk of BCR, and the risk was stronger among men with a high BMI. In contrast, the use of metformin alone or in combination with statins was not associated with BCR. Together, this suggests that statins may be associated with worse prostate cancer outcomes in diabetic men, but these risks may be mitigated by concomitant use of metformin.
Future studies are needed to confirm our findings, and if verified, then to help understand the basis for these associations.
Clinical Practice Points
Metformin and statins are widely provided to patients with diabetes, and they may affect the risk of BCR after RP. Little is known about how preoperative combination therapy with these drugs can potentially affect the oncologic outcome of prostatectomy. When adjusted for key demographic, clinical, and pathologic features as well as the HbA1c level (as a marker of overall serum glucose level control), preoperative use of statins is associated with a higher risk of BCR, and the risk was stronger among men with a high BMI. In contrast, the use of metformin alone or in combination with statins is not associated with BCR. Regardless of the race, statins may be associated with worse postprostatectomy outcomes in diabetic men, but these risks may be mitigated by concomitant use of metformin. Supplemental 
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